Diabetes News Archive

Genetic and molecular dissection of a rat model of diabetes implicates the {alpha}2A-adrenergic receptor in insulin secretion and susceptibility to type 2 diabetes.

To the Editor: The trial of treatment of mild gestational diabetes mellitus showed no difference in primary outcomes (Oct. 1 ...

A prospective study of Group Health primary-care patients with diabetes in western Washington showed that depression raised the risks of advanced and severe complications from diabetes during a five-year follow-up

( University of Washington ) A prospective study of Group Health primary-care patients with diabetes in western Washington showed that depression raised the risks of advanced and severe complications from diabetes during a five-year follow-up

Depression increases the risk of kidney failure, blindness, heart attacks and stroke in people with diabetes.

Jan. 27, 2010 - Victoza (liraglutide), a drug intended to help lower blood sugar levels along with diet, exercise, and selected other diabetes medicines, was approved on January 25 for a once-daily injection to treat type 2 diabetes in some adults..

Title: Victoza Sanctioned for Type 2 Diabetes Category: Health News Created: 1/26/2010 2:10:00 PM Last Editorial Review: 1/27/2010

LOS ANGELES, CA--(Marketwire - January 27, 2010) - The Joe Toucan Diabetes Project, a 501(c)(3) organization focused on researching, producing, and developing empowering projects, supplies and accessories for children and young adults living with diabetes, announces that Los Angeles Lakers forward Adam Morrison will be joining its advisory board. Morrison, a first round selection in the 2005 NBA ...

Moderation appears to be the best approach to controlling blood sugar in a form of diabetes that affects many adults, researchers said Wednesday, since lowering it too far can be as risky as letting it stay too high.

ALEXANDRIA, VA--(Marketwire - January 27, 2010) - Having diabetes can feel like a balancing act among blood glucose (sugar) levels, food, exercise and the ways in which each of these elements affects day-to-day life. Add to this more than 12 hours of dancing each day in pointe shoes, late-night performances and flip-flopping diagnoses, and it's no wonder that ballerina Zippora Karz "felt like a ...

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amylin/Eli Lilly/Alkermes' Byetta LAR earns Decision Resources' proprietary clinical gold standard status in 2013 for the treatment of type 2 diabetes following its approval for the indication in 2010. Byetta LAR has competitive advantages over currently available and ...

In people who put on a lot of weight, or whose bodies start developing the inability to use insulin effectively that leads toward type 2 diabetes, the pancreas typically ramps up its supply of insulin-generating "beta" cells, at least partly by replication of the existing cells. Researchers at Joslin Diabetes Center and their colleagues now have identified a cell-cycle protein that is essential ...

People with lower socioeconomic status and those belonging to ethnic minority groups receive worse health care in the treatment of diabetes than the rest of patients in the world's most developed countries.

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza(R) (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus...

An article Online First and in an upcoming edition of The Lancet reports that new research indicates that intensive treatment to control blood glucose can lower it too far and cause hypoglycaemia. This can increase mortality. Uncontrolled high blood glucose (hyperglycaemia) in patients with diabetes is known to also increase mortality. Therefore in order to lower the risk to patients, blood ...

Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of ...

People with diabetes or who are at risk of developing the disease - now estimated at over 400 million globally - could reduce complications, improve quality of life and reduce healthcare costs by using new non-invasive technology to screen for and monitor the illness, according to a presentation by Freedom Meditech at the 6th Annual Diabetes and Diabetic Retinopathy Conference in London, England ...

Shares of Indianapolis-based Eli Lilly and Co. and Amylin Pharmaceuticals, its San Diego-based partner on diabetes treatment Byetta, moved higher Tuesday after federal health officials' approval of Danish drug maker Novo Nordisk's once-daily injection gave hope that approval could come soon for once-weekly Byetta.

Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments ...

The U.S. Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults.

Novo Nordisk, a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza(R) (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with ...

Doctors have a new tool in the arsenal against diabetes. The FDA just approved a new drug called Victoza. The drug is designed for folks who have developed adult onset diabetes.

Intense treatment to lower blood sugar in patients with diabetes could prove nearly as harmful as allowing glucose levels to remain high, a study finds.

Intense treatment to lower blood sugar in diabetes patients may prove nearly as harmful as leaving glucose levels high, study finds.

Moderation appears to be the best approach to controlling blood sugar in a form of diabetes that affects many adults, researchers said Wednesday, since lowering it too far can be as risky as letting it stay too high.